Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Postural sway, falls, and self-reported neuropathy in aging female cancer survivors.

Fino PC, Horak FB, El-Gohary M, Guidarelli C, Medysky ME, Nagle SJ, Winters-Stone KM.

Gait Posture. 2019 Mar;69:136-142. doi: 10.1016/j.gaitpost.2019.01.025. Epub 2019 Jan 17.

PMID:
30716669
2.

Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.

Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J.

Cytotherapy. 2018 Dec;20(12):1415-1418. doi: 10.1016/j.jcyt.2018.10.003. Epub 2018 Oct 29.

PMID:
30385043
3.

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS.

Nagle SJ, Shah NN, Ganetsky A, Landsburg DJ, Nasta SD, Mato A, Schuster SJ, Reshef R, Tsai DE, Svoboda J.

Int J Hematol Oncol. 2017 Dec;6(4):113-121. doi: 10.2217/ijh-2017-0020. Epub 2018 Jan 26.

4.

Posttransplant Lymphoproliferative Disorder in Solid Organ and Hematopoietic Stem Cell Transplantation.

Nagle SJ, Reshef R, Tsai DE.

Clin Chest Med. 2017 Dec;38(4):771-783. doi: 10.1016/j.ccm.2017.08.001. Epub 2017 Sep 21. Review.

PMID:
29128025
5.

Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.

Bair SM, Strelec L, Nagle SJ, Nasta SD, Landsburg DJ, Mato AR, Loren AW, Schuster SJ, Stadtmauer EA, Svoboda J.

Am J Hematol. 2017 Sep;92(9):879-884. doi: 10.1002/ajh.24792. Epub 2017 Jun 9.

6.

The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.

Nagle SJ, Garfall AL, Stadtmauer EA.

Cancer J. 2016 Jan-Feb;22(1):27-33. doi: 10.1097/PPO.0000000000000166. Review.

7.

The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.

Nagle SJ, Chong EA, Chekol S, Shah NN, Nasta SD, Glatstein E, Plastaras JP, Torigian DA, Schuster SJ, Svoboda J.

Cancer Med. 2015 Jan;4(1):7-15. doi: 10.1002/cam4.322. Epub 2014 Sep 10.

8.

Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.

Nagle SJ, Woo K, Schuster SJ, Nasta SD, Stadtmauer E, Mick R, Svoboda J.

Am J Hematol. 2013 Oct;88(10):890-4. doi: 10.1002/ajh.23524. Epub 2013 Aug 1.

9.

A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.

Mendoza FA, Nagle SJ, Lee JB, Jimenez SA.

J Rheumatol. 2012 Jun;39(6):1241-7. doi: 10.3899/jrheum.111229. Epub 2012 Apr 1.

PMID:
22467932
10.

Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo.

Kutzler MA, Kraynyak KA, Nagle SJ, Parkinson RM, Zharikova D, Chattergoon M, Maguire H, Muthumani K, Ugen K, Weiner DB.

Gene Ther. 2010 Jan;17(1):72-82. doi: 10.1038/gt.2009.112. Epub 2009 Oct 22.

PMID:
19847203

Supplemental Content

Loading ...
Support Center